Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant for chronic migraine with comorbid insomnia
ACTRN12626000081314Phase 4Not yet recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daridorexant in migraine and Insomnia, sponsored by Sunnybrook Health Sciences Centre. Primary endpoints: Change in Monthly Migraine Days and Change in Monthly Headache Days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
daridorexant
03
Conditions
migraineInsomnia
Beyond the preview
Go deeper on ACTRN12626000081314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000081314.